IDRSF News and Press, Idorsia AG From 10/24/23

2023-10-24 09:30:11 ET More on Idorsia Idorsia's Insomniac Earnings And The Sell Signal That Won't Sleep Idorsia Ltd 2023 Q2 - Results - Earnings Call Presentation Idorsia Ltd (IDRSF) Q2 2023 Earnings Call Transcript Historical earnings data for Idorsia ...

2023-09-05 05:56:45 ET Summary Idorsia's Q2 2023 earnings and sales were below expectations, leading to concerns about the company's financial position. Sales growth for Idorsia's anti-insomnia drug, daridorexant, has been slow and disappointing, and no sign things will get better...

2023-07-29 12:53:06 ET Idorsia Ltd (IDRSF) Q2 2023 Earnings Conference Call July 25, 2023 09:00 AM ET Company Participants Andrew Weiss - Head of IR Jean-Paul Clozel - CEO Andre Muller - EVP & CFO Patricia Torr - VP, Head of US Finance & Infrastructur...

2023-07-26 05:51:17 ET Summary Idorsia announced a cost reduction target to reduce operating expenses by approximately 50%. Idorsia also sold its APAC (ex-China) license for CHF 400 million to extend its cash burn until 2024. We confirmed our Idorsia stock's neutral rating. Pr...

2023-07-25 09:43:33 ET Idorsia press release ( OTC:IDRSF ): 1H GAAP EPS of -CHF2.28. Revenue of CHF51M (+131.8% Y/Y). For further details see: Idorsia GAAP EPS of -CHF2.28, revenue of CHF51M

Allschwil, Switzerland – June 2 6 , 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, were presented as ...

2023-06-10 09:22:00 ET Summary Idorsia missed sales expectations by 47% and is urgently seeking funding to avoid equity issuance. We have cut our Quviviq sales expectations and pushed out the timeline to profitability to 2026. We downgrade Idorsia to neutral with a 12-month ta...

2023-04-30 23:57:33 ET Summary Downgrade to Sell: Due to lower-than-expected sales of Quviviq and clazosentan (Pivlaz), high cash burn, and a short cash runway, we are downgrading our rating on Idorsia stock to Sell. Disappointing Q1 2023 Results: Idorsia's Q1 performance fell sho...

2023-04-26 13:31:36 ET Idorsia press release ( OTC:IDRSF ): Q1 GAAP EPS of -CHF1.19. Revenue of CHF21M (+320.0% Y/Y). For further details see: Idorsia GAAP EPS of -CHF1.19, revenue of CHF21M

2023-04-26 11:35:44 ET Summary Idorsia missed top-line sales estimates. Only a quarter of liquidity, there was no funding news, and this increased the risk of equity dilution. Idorsia confirmed its 2025 financial targets but is lagging behind 2023 sales. Idorsia ( ...